Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
Key facts
- Who runs it
- Beni-Suef University
- Where
- Egypt2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 240 people enrolled
- Started
- 5 Jun 2024
- Ended
- 1 Nov 2025
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Myoinositol
- Chromium
- l-arginine
- Letrozole 2.5mg
- Record updated
- 12 November 2026
Who can take part
- Age
- 20 years to 40 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Primary or secondary infertility associated with PCOS as defined by the revised Rotterdam criteria
- Normal values of the following laboratory tests: thyroid function, prolactin level, and husband's sperm analysis and hysterosalpingography
Who cannot take part
- Patients who consumed myoinositol, metformin, SGLT2 or drugs effecting insulin secretion or clomiphene citrate in the previous 2 months
- Use of hormonal medications, lipid-lowering agents (statins, etc.), anti-obesity drugs or medications for weight loss in the previous 2 months
- Patients with a history of systemic diseases such as liver, kidney, cardiovascular, diabetes (type I or II) or malignancy
- Patients with hormonal disorders such as hyperprolactinemia, hypo or hyperthyroidism or Cushing syndrome. 5. Presence of hypersensitivity to any of the study medications
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of the study is to compare and assess the efficacy of combined letrozole with myoinositol, chromium, or L-arginine in infertile women with PCOS. This study will help in the investigation of alternative therapeutic modalities for fertility improvement in polycystic ovarian syndrome
The 4 groups in the trial
- myoinositolTreatment being tested
patients will be treated for 12 weeks myoinositol (2gm /day) with ovulation induction by letrazole regimen for 3 consecutive cycl
Treatment: Myoinositol and Letrozole 2.5mg
- chromiumTreatment being tested
patients will be treated for 12 weeks one capsule daily of 200 µg chromium picolinate (24.85 µg elemental chromium) with ovulation induction by letrazole regimen for 3 consecutive cycles
Treatment: Chromium and Letrozole 2.5mg
- L-arginineTreatment being tested
: patients will be treated for 12 weeks with L-arginine (500 mg once daily in the morning) with ovulation induction by letrazole regimen for 3 consecutive cycles.
Treatment: l-arginine and Letrozole 2.5mg
- controlPlacebo, for comparison
ovulation induction by letrazole regimen for 3 consecutive cycles.
Treatment: Letrozole 2.5mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Combination of Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients
- Record updated
- 12 November 2026